Drugmaker Teva does not see big impact on business from Israel-Hamas war | Reuters
Teva 'Plagued By Problems,' Downgraded On Lost MS Drug Patents, DOJ Probe | Stock News & Stock Market Analysis - IBD
Teva Pharmaceuticals to pay New York $523 million to settle claims from its role in opioids crisis - ABC News
Teva to pay New York $500M for role in opioid crisis - POLITICO
Teva to pay $225M to settle cholesterol drug price-fixing charges | AP News
Closure of another criminal case will help Teva's new CEO to focus on return to growt | Ctech
Teva, one of the biggest generic makers, joins the the brand-name club
Teva Pharmaceuticals found to be responsible for its role in the opioid epidemic in New York State | CNN
Teva Pharmaceuticals Agrees To $85 Million Settlement With Oklahoma In Opioid Case | KPBS Public Media
Teva profit plummets, stock slides | Ctech
Teva's Richard Francis launches 'pivot to growth' strategy | Fox Business Video
Opioid firm Teva agrees $85m settlement days before Oklahoma case goes to court | US News | Sky News
Teva Pharmaceuticals to pay New York $523 million to settle claims from its role in opioids crisis - KTSA
Teva Pharmaceutical (TEVA) bets on market reopening to regain momentum | AlphaStreet
Teva Rockets After Hiring Former Novo Nordisk Exec As CEO | Investor's Business Daily
Teva says Israel-Hamas war not hurting production, eyes growth in 2024 | Reuters
Teva reaches $126M opioid settlement with hospitals - Top Class Actions
Teva to pay $225 million fine and divest cholesterol drug to settle price-fixing charges | CNN Business
Teva Pharmaceutical to Nominate Four New Directors - WSJ
Teva Reaches Tentative $4.25 Billion Settlement Over Opioids - The New York Times
Teva CEO Richard Francis on Q2 earnings beat - YouTube
Suffering from missteps, drugmaker Teva struggles to heal own ills | The Times of Israel
Teva Pharmaceutical posts rise in Q3 2023 net income to $80m
Teva Eyes 25 Percent of the $750 Million EpiPen Market by Year's End | BioSpace
Teva Pharmaceutical Industries (TEVA) Stock Price, News & Info | The Motley Fool
Corcept Therapeutics plunges amid patent trial with Teva (NASDAQ:CORT) | Seeking Alpha
